The data to be presented will include new in-vivo evidence of the efficacy of Prana Biotechnology's (PBT) PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for the company's PBT434.
http://crweworld.com/article/news-p...-of-parkinsons-disease-and-movement-disorders
Ann: Prana to present PBT434 data at International Congress, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $147.3M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.8¢ | 1.5¢ | $787.6K | 48.96M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 9250665 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 6931087 | 13 |
View Market Depth
| Last trade - 16.11pm 28/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |